These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16967346)

  • 21. Pulsatile intravenous gonadotropin-releasing hormone administration averts fasting-induced hypogonadotropism and hypoandrogenemia in healthy, normal weight men.
    Aloi JA; Bergendahl M; Iranmanesh A; Veldhuis JD
    J Clin Endocrinol Metab; 1997 May; 82(5):1543-8. PubMed ID: 9141547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Model-Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk.
    Sannala CKR; MacLean C; Larsen F; van Os S; Jadhav P; Shore N; Morgans AK; Okwuosa T; Gobburu J
    Clin Pharmacol Drug Dev; 2024 Aug; 13(8):915-929. PubMed ID: 38757461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of decreasing the frequency of gonadotropin-releasing hormone stimulation on gonadotropin secretion in gonadotropin-releasing hormone-deficient men and perifused rat pituitary cells.
    Finkelstein JS; Badger TM; O'Dea LS; Spratt DI; Crowley WF
    J Clin Invest; 1988 Jun; 81(6):1725-33. PubMed ID: 3290251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
    Ozono S; Ueda T; Hoshi S; Yamaguchi A; Maeda H; Fukuyama Y; Takeda K; Ohashi Y; Tsukamoto T; Naito S; Akaza H
    Jpn J Clin Oncol; 2012 Jun; 42(6):477-84. PubMed ID: 22457321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Testosterone differentially modulates gonadotropin subunit messenger ribonucleic acid responses to gonadotropin-releasing hormone pulse amplitude.
    Iliff-Sizemore SA; Ortolano GA; Haisenleder DJ; Dalkin AC; Krueger KA; Marshall JC
    Endocrinology; 1990 Dec; 127(6):2876-83. PubMed ID: 1701131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Age diminishes the testicular steroidogenic response to repeated intravenous pulses of recombinant human LH during acute GnRH-receptor blockade in healthy men.
    Veldhuis JD; Veldhuis NJ; Keenan DM; Iranmanesh A
    Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E775-81. PubMed ID: 15572655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A preponderance of circulating basic isoforms is associated with decreased plasma half-life and biological to immunological ratio of gonadotropin-releasing hormone-releasable luteinizing hormone in obese men.
    Castro-Fernández C; Olivares A; Söderlund D; López-Alvarenga JC; Zambrano E; Veldhuis JD; Ulloa-Aguirre A; Méndez JP
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4603-10. PubMed ID: 11134115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing subcutaneous injection of the gonadotropin-releasing hormone receptor antagonist degarelix.
    Barkin J; Burton S; Lambert C
    Can J Urol; 2016 Feb; 23(1):8179-83. PubMed ID: 26892063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subcutaneous administration of gonadotropin-releasing hormone: absorption kinetics and gonadotropin responses.
    Hurley DM; Clarke IJ; Shelton R; Burger HG
    J Clin Endocrinol Metab; 1987 Jul; 65(1):46-52. PubMed ID: 3108305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sex steroid control of gonadotropin secretion in the human male. II. Effects of estradiol administration in normal and gonadotropin-releasing hormone-deficient men.
    Finkelstein JS; O'Dea LS; Whitcomb RW; Crowley WF
    J Clin Endocrinol Metab; 1991 Sep; 73(3):621-8. PubMed ID: 1908485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Testosterone is required for gonadotropin-releasing hormone stimulation of luteinizing hormone-beta messenger ribonucleic acid expression in female rats.
    Yasin M; Dalkin AC; Haisenleder DJ; Marshall JC
    Endocrinology; 1996 Apr; 137(4):1265-71. PubMed ID: 8625898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of long-acting GnRH antagonist, degarelix acetate, on plasma insulin-like peptide 3, testosterone and luteinizing hormone concentrations, and scrotal circumference in male goats.
    Hannan MA; Kawate N; Fukami Y; Weerakoon WW; Büllesbach EE; Inaba T; Tamada H
    Theriogenology; 2017 Jan; 88():228-235. PubMed ID: 27793455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Degarelix: a new approach for the treatment of prostate cancer.
    Persson BE; Kold Olesen T; Jensen JK
    Neuroendocrinology; 2009; 90(3):235-44. PubMed ID: 19602868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effects of two different delivery systems on gonadotropin-releasing hormone (GnRH) antagonist-induced suppression of gonadotropins and testosterone in man.
    Salameh W; Bhasin S; Steiner BS; McAdams LA; Peterson M; Rivier JE; Vale WW; Swerdloff RS
    J Androl; 1994; 15(1):22-8. PubMed ID: 8188535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low dose pulsatile gonadotropin-releasing hormone in anorexia nervosa: a model of human pubertal development.
    Marshall JC; Kelch RP
    J Clin Endocrinol Metab; 1979 Nov; 49(5):712-8. PubMed ID: 385613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-finding study of daily gonadotropin-releasing hormone (GnRH) antagonist for the prevention of premature luteinizing hormone surges in IVF/ICSI patients: antide and hormone levels.
    Huirne JA; van Loenen AC; Schats R; McDonnell J; Hompes PG; Schoemaker J; Homburg R; Lambalk CB
    Hum Reprod; 2004 Oct; 19(10):2206-15. PubMed ID: 15333605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative response of rams and bulls to long-term treatment with gonadotropin-releasing hormone analogs.
    Jiménez-Severiano H; D'Occhio MJ; Lunstra DD; Mussard ML; Davis TL; Enright WJ; Kinder JE
    Anim Reprod Sci; 2007 Apr; 98(3-4):204-24. PubMed ID: 16616998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential regulation of serum immunoreactive luteinizing hormone and bioactive follicle-stimulating hormone by testosterone in early pubertal boys.
    Hassing JM; Padmanabhan V; Kelch RP; Brown MB; Olton PR; Sonstein JS; Foster CM; Beitins IZ
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1082-9. PubMed ID: 2108181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer.
    Anderson J
    Future Oncol; 2009 May; 5(4):433-43. PubMed ID: 19450172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, alpha subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix).
    Andreyko JL; Monroe SE; Marshall LA; Fluker MR; Nerenberg CA; Jaffe RB
    J Clin Endocrinol Metab; 1992 Feb; 74(2):399-405. PubMed ID: 1370507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.